Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
A phase 2 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Rigshospitalet, Denmark, with a status the registry has not verified recently.
Overview
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms is a phase 2 interventional study registered as NCT05709171 by Rigshospitalet, Denmark, with 200 participants planned, started 2023-01-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: 18F-FDG, 64Cu-Dotatate. Conditions recorded: GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic.
Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialImaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Shares Somatostatin receptor PET (68Ga/64Cu-DOTATATE), Neuroendocrine tumours and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Shares Neuroendocrine tumours and the tag pipeline.
- Trial68Ga-DOTA-TATE PET/CT Imaging in NETs
Shares Neuroendocrine tumours and the tag pipeline.
- TrialTelotristat With Lutathera in Neuroendocrine Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Study of PM8002 in Combination With Chemotherapy in Patients With NEN
Shares Neuroendocrine tumours and the tag pipeline.
- TrialA Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Shares Neuroendocrine tumours and the tag pipeline.
- TrialDose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Shares Neuroendocrine tumours and the tag pipeline.